The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Peer Review reports

Original Submission
8 Aug 2018	Submitted	Original manuscript
28 May 2019	Reviewed	Reviewer Report - Nicole Chanel Solomon
24 Aug 2019	Reviewed	Reviewer Report - Andrew Gray
28 Aug 2019	Reviewed	Reviewer Report - Kim Madden
10 Oct 2019	Author responded	Author comments - Samantha Hinsley
Resubmission - Version 2
10 Oct 2019	Submitted	Manuscript version 2
22 Oct 2019	Reviewed	Reviewer Report - Nicole Chanel Solomon
24 Oct 2019	Reviewed	Reviewer Report - Andrew Gray
28 Oct 2019	Reviewed	Reviewer Report - Kim Madden
12 Dec 2019	Author responded	Author comments - Samantha Hinsley
Resubmission - Version 3
12 Dec 2019	Submitted	Manuscript version 3
4 Jan 2020	Reviewed	Reviewer Report - Andrew Gray
20 Feb 2020	Author responded	Author comments - Samantha Hinsley
Resubmission - Version 4
20 Feb 2020	Submitted	Manuscript version 4
5 Mar 2020	Reviewed	Reviewer Report - Andrew Gray
6 May 2020	Author responded	Author comments - Samantha Hinsley
Resubmission - Version 5
6 May 2020	Submitted	Manuscript version 5
2 Jun 2020	Reviewed	Reviewer Report - Andrew Gray
Resubmission - Version 6
	Submitted	Manuscript version 6
Publishing
12 Sep 2020	Editorially accepted
2 Oct 2020	Article published	10.1186/s13063-020-04739-8

Back to article page